Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis

NCT06559150 is registered in ClinicalTrials.gov with Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA as lead sponsor.

NCT NCT06559150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06559150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase
Phase 2
Overall status
Recruiting
Start date
September 11, 2024
Completion date
September 24, 2027
Enrollment
284 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

non-cystic fibrosis bronchiectasis